VivoSim Labs (VIVS) Cost of Revenue (2011 - 2024)

VivoSim Labs (VIVS) posted Cost of Revenue of $2000.0 for Q4 2024, up 100.0% on a QoQ basis from $1000.0 in Q3 2024.

Analysis

VivoSim Labs (VIVS) Cost of Revenue (2011 - 2024) Analysis & Trends

VivoSim Labs has reported Cost of Revenue for 6 years, with the latest figure at $2000.0 in Q4 2024.

On a quarterly basis, Cost of Revenue changed N/A year-over-year to $2000.0 in Q4 2024; TTM through Sep 2025 was $2000.0, a 33.33% decrease from a year earlier, with the FY2025 full-year figure at $5000.0, changed N/A from the prior year.
Cost of Revenue was $2000.0 for Q4 2024 at VivoSim Labs, up from $1000.0 in the prior quarter.
The five-year high for Cost of Revenue was $2000.0 in Q2 2024, with the low at $1000.0 in Q3 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Iqvia Holdings	42.77 Bn	40.69 Bn	1.44 Bn	2.93 Bn
2	Medpace Holdings	16.50 Bn	16.00 Bn	201.64 Mn	505.69 Mn
3	Charles River Laboratories International	13.37 Bn	13.18 Bn	452.07 Mn	552.01 Mn
4	Icon	12.49 Bn	11.56 Bn	479.29 Mn	1.58 Bn
5	Fortrea Holdings	1.58 Bn	1.42 Bn	139.20 Mn	539.00 Mn
6	Evotec SE	642.83 Mn	216.96 Mn	-	-
7	Ginkgo Bioworks Holdings	422.55 Mn	338.02 Mn	18.44 Mn	1.72 Mn
8	Champions Oncology	69.16 Mn	69.16 Mn	7.03 Mn	6.81 Mn
9	MindWalk Holdings	59.83 Mn	51.55 Mn	1.82 Mn	1.18 Mn
10	VivoSim Labs	1.45 Mn	1.45 Mn	-	-

Historic Data

Download Data